Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christof Scheid

Showing results (171-180 of 200) with videos related to

Pageof 20
Sort By:
Frontiers in Immunology|February 19, 2021
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell MalignanciesAgnieszka Tomaszewska, Madan Jagasia, Eric Beohou, et al.
Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Bone Marrow Transplantation|May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working PartiesPeter Dreger, Mauricette Michallet, Paul Bosman, et al.
Blood Cancer Journal|January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaMarc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
American Journal of Hematology|May 26, 2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trialDietrich W Beelen, Matthias Stelljes, Péter Reményi, et al.
Bone Marrow Transplantation|March 28, 2023
The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMTOlivier Tournilhac, Michel van Gelder, Dirk-Jan Eikema, et al.
Blood|May 10, 2024
Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?Christof Scheid, Diderik-Jan Eikema, Michel van Gelder, et al.
Blood Advances|February 8, 2024
Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMTCarmelo Gurnari, Linda Koster, Laurien Baaij, et al.
Haematologica|January 2, 2008
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myelomaHenk M Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, et al.
Haematologica|September 3, 2013
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trialChristof Scheid, Pieter Sonneveld, Ingo G H Schmidt-Wolf, et al.
Pageof 20

Showing results (171-180 of 200) with videos related to

Sort By:
Pageof 20
Frontiers in Immunology|February 19, 2021
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell MalignanciesAgnieszka Tomaszewska, Madan Jagasia, Eric Beohou, et al.
Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Bone Marrow Transplantation|May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working PartiesPeter Dreger, Mauricette Michallet, Paul Bosman, et al.
Blood Cancer Journal|January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaMarc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
American Journal of Hematology|May 26, 2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trialDietrich W Beelen, Matthias Stelljes, Péter Reményi, et al.
Bone Marrow Transplantation|March 28, 2023
The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMTOlivier Tournilhac, Michel van Gelder, Dirk-Jan Eikema, et al.
Blood|May 10, 2024
Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?Christof Scheid, Diderik-Jan Eikema, Michel van Gelder, et al.
Blood Advances|February 8, 2024
Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMTCarmelo Gurnari, Linda Koster, Laurien Baaij, et al.
Haematologica|January 2, 2008
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myelomaHenk M Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, et al.
Haematologica|September 3, 2013
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trialChristof Scheid, Pieter Sonneveld, Ingo G H Schmidt-Wolf, et al.
Pageof 20